http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005098024-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a75fb6b4c5dcfb142543be52ab6e35e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f69c89ed3a6242213905509fb62e0206 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0549d7b7aece5a26fc8a7b8239ca6a86 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
| filingDate | 2005-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba23c51c8a4a331fc568af5065738707 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_818f97d053af503f98696a10d9e7576e |
| publicationDate | 2005-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005098024-A1 |
| titleOfInvention | In vivo measurement of the relative fluxes through ribonucleotide reductase vs. deoxyribonucleoside pathways using isotopes |
| abstract | The methods of the present invention allow for the measurement of ribonucleotide reductase (RR) activity, an important enzyme in the de novo DNA synthesis pathway. Ribonucleotide reductase converts all four ribonucleotides to their deoxy form and is a rate-controlling step in this pathway. Biosynthetic pathways of deoxyribonucleotides (dN) have received considerable attention in the context of anti-proliferative chemotherapy. Inhibitors of various steps in dN biosynthesis, including inhibitors of RR are among the most useful chemotherapeutic agents in cancer, viral infections, and other therapeutic uses. DNA synthesis from the dN salvage pathway is also an important component to DNA replication. The relative contributions from RR vs. salvage pathways are critical to the actions and effectiveness of chemotherapeutic agents that act on nucleoside metabolic pathways. Until now, however, it has not been possible to study these metabolic processes in vivo. Disclosed within are methods of measuring RR activity in vivo and in vitro which find use, among other things, in drug discovery, development, and approval. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008024052-A1 |
| priorityDate | 2004-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1017.